20 clinical trials matched your search for Kidney Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Kidney Cancer Study of Experimental Drug (Axitinib) in Patients with Metastatic Pheochromocytoma (PCC) or Paraganglioma Antonio Fojo, MD, PhD
Kidney Cancer Study of Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients with Localized Clear Cell Renal Cell Carcinoma Karie D. Runcie, MD
Kidney Cancer Cyto-KIK Trial: CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition Mark Stein, MD
Kidney Cancer Study of XmAb819 in Patients with Clear Cell Renal Cell Carcinoma Karie D. Runcie, MD
Cancer Early Onset Malignancies Initiative (EOMI) Bret Taback, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Catherine Shu, MD
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Autoimmune Disorders Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Cancer Study of Investigational Drug (RP-6306) in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Shaheer Khan, DO
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors Benjamin Izar, MD
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors Karie D. Runcie, MD
Cancer Study of MRT-2359 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation Benjamin Herzberg, MD